Author Archives for Adeline Chauvigné

Valneva and Pfizer complete recruitment for Phase 2 Trial of Lyme disease vaccine candidate

27 July 2021

Valneva, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet... View Article

OSE Immunotherapeutics announces voluntary pause of enrollment in the CoVepiT Phase 1 study

27 July 2021

OSE Immunotherapeutics today announced a voluntary and temporary pause of enrollment and dosing in its ongoing Phase 1 clinical trial... View Article

OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank

27 July 2021

This financing will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in therapeutic areas with... View Article

Mérieux NutriSciences sells the European activities of Biofortis to its managing director who will continue its development alongside Institut Mérieux

27 July 2021

Mérieux NutriSciences sells the European activities of Biofortis to its managing director who will continue its development alongside Institut Mérieux... View Article

Valneva continues ongoing discussions with the European Commission for inactivated COVID-19 vaccine candidate

27 July 2021

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article

French biotech XENOTHERA accelerates its development with fundraising of 20 million euros

27 July 2021

XENOTHERA is developing a technological platform of exclusive “glyco-humanized” antibodies built on dual expertise in genetics and immunology. The financing... View Article

OSE Immunotherapeutics announces manufacturing agreement with Cenexi for clinical batches of CoVepiT, OSE’s multi-target second-generation COVID-19 vaccine

27 July 2021

OSE Immunotherapeutics and Cenexi, a French contract development and manufacturing organization (CDMO), today announced the signature of an agreement whereby... View Article

GlioCure strengthens its management team with the recruitment of Dr. Sandrine Courtès as Director of Preclinical Development and Intellectual Property

27 July 2021

GlioCure SA, a biotechnology company specializing in neuro-oncology, announces the arrival of Dr. Sandrine Courtès, a researcher-entrepreneur dedicated to brain... View Article

InFlectis BioScience licenses rights to a potential new class of therapies for demyelinating diseases from the University of Chicago

27 July 2021

InFlectis BioScience has been granted exclusive patent rights from the University of Chicago to use a family of small molecules for the treatment... View Article

Jessica Walker has been elected Board Member of the Council of European Bioregions!

27 July 2021

Atlanpole Biotherapie’s European project manager Jessica Walker has been elected Board Member of the Council of European Bioregions! This European... View Article